PURE Bioscience, Inc.

Item 5.07. Submission of Matters to a Vote of Security Holders. Pure Bioscience, Inc. (the “Company”) held its Annual Meeting of Stockholders (the “Annual Meeting”) on February 17, 2026. Of the 111,886,485 shares of the Company’s common stock outstanding as of the record date, 73,820,863 shares, or 65.97%, were represented at the Annual Meeting either in person or by proxy. A description of each matter voted upon at the Annual Meeting is described in detail in the Proxy Statement. The number of votes cast “For” and “Withheld” and “Against” and the number of “Abstentions” and “Broker Non-Votes” with respect to each matter voted upon are set forth below. (1) Election of Directors. The Company’s stockholders elected each of Tom Y. Lee, CPA, Ivan Chen, Tom Myers, David M. Rendall, Robert Bartlett, Bernard Blotner and Darin Zehr with the approval of 97.82%, 98.07%, 96.52%, 96.83%, 96.55%, 96.85% and 96.86%, of the votes cast, respectively, to hold office until next year’s Annual Meeting of Stockholders and until their respective successors are elected and qualified. The following table shows the tabulation of the votes cast For and Withheld with respect to the election of each of the director nominees as well as the Broker Non-Votes submitted for each director nominee: Director For Withheld Broker Non-Votes ─────────────────────────────────────────────────────────────────── Tom Y. Lee, CPA 59,860,307 1,332,527 12,628,029 Ivan Chen 60,011,852 1,180,982 12,628,029 Tom Myers 59,061,293 2,131,541 12,628,029 David M. Rendall 59,253,062 1,939,772 12,628,029 Robert Bartlett 59,080,819 2,112,015 12,628,029 Bernard Blotner 59,262,655 1,930,179 12,628,029 Darin Zehr 59,273,777 1,919,057 12,628,029 (2) Ratification of Auditors. The Company’s stockholders ratified the appointment of Weinberg & Company, P.A., with the approval of 99.81% of the votes cast, as the Company’s independent registered public accounting firm for the fiscal year ending July 31, 2026. The following table shows the tabulation of the votes cast For and Against this proposal as well as the Abstentions submitted on this proposal: For Against Abstentions ──────────────────────────────────────────── 73,008,365 137,649 674,849 (3) Executive Compensation. The Company’s stockholders, on a non-binding, advisory basis, approved the compensation of the Company’s named executive officers, with the approval of 96.68% of the votes cast, as disclosed in the Proxy Statement. The following table shows the tabulation of the votes cast For and Against this proposal as well as the Abstentions and Broker Non-Votes submitted on this proposal: For Against Abstentions Broker Non-Votes ────────────────────────────────────────────────────────────── 58,428,196 2,000,989 763,649 12,628,029 4) Amendment to Certificate of Incorporation. The Company’s stock-holders approved an amendment to our Certificate of Incorporation to increase the authorized number of shares of Common Stock from 200,000,000 to 250,000,000 shares, with the approval of 63.87% of the outstanding shares of common stock, as disclosed in the Proxy Statement. The following table shows the tabulation of the votes cast For and Against this proposal as well as the Abstentions submitted on this proposal: For Against Abstentions ────────────────────────────────────────────── 71,472,843 2,298,269 49,751 No other items were presented for stockholder approval at the Annual Meeting.